Forecasting The Future: 13 Analyst Projections For Nurix Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past three months, 13 analysts have evaluated Nurix Therapeutics (NASDAQ:NRIX), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased to $29.54, reflecting a 6.64% rise from the previous target. Analysts have adjusted their ratings and price targets, with notable actions including Truist Securities announcing a 'Buy' rating with a $36.00 target and JP Morgan raising its target to $34.00. Despite revenue challenges and below-average ROE and ROA, Nurix maintains a balanced debt approach.
July 31, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nurix Therapeutics (NASDAQ:NRIX) has received mixed analyst ratings over the past three months, with a current average price target of $29.54, up 6.64% from the previous target. Key ratings include Truist Securities' 'Buy' at $36.00 and JP Morgan's 'Overweight' at $34.00. Despite revenue challenges and below-average ROE and ROA, the company maintains a balanced debt approach.
The increase in the average price target and the majority of ratings being bullish or somewhat bullish suggest a positive short-term impact on NRIX's stock price. However, the company's revenue challenges and below-average ROE and ROA may temper this optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100